A Phase 4 interventional study of sevoflurane and propofol in Delayed Graft Function, Renal Outcome After Kidney Transplantation and Acute Rejection (AR) of Transplanted Kidney, sponsored by University Medical Center Groningen. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by University Medical Center Groningen · Phase 4, Interventional, and Treatment
To compare the effect of a sevoflurane based anesthesia versus a propofol based anesthesia on the incidence of DGF in recipients of kidneys of donation after circulatory death (DCD) and donation after brain death (DBD) donors
Objective:
To compare the effect of a sevoflurane based anaesthesia versus a propofol based anaesthesia on the incidence of delayed graft function in recipients of DCD and DBD donor kidneys.
Study design:
Prospective randomized controlled European multicentre clinical trial with two parallel groups
Study population:
Patients ≥18 years scheduled for kidney transplantation with a kidney from a DBD or DCD donor
Intervention:
Patients will be included and randomised to one of the following groups:
Group 1 PROP (control): Propofol: a propofol-remifentanil based anaesthesia. Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based anaesthesia.
Main study parameters:
Primary outcome: The two co-primary endpoints are the incidence of DGF and one-year acute rejection in recipients of DCD and DBD donor kidneys. DGF is defined as need for dialysis within the first week after transplantation, excluding one-time dialysis for hyperkalaemia. Acute rejection is defined by the modified BANFF 2013 classification and must be associated with decline in kidney function and treatment.
Secondary outcomes Functional delayed graft function (fDGF) is defined as the absence of a daily decrease of at least 10% in serum creatinine for at least three consecutive days; primary non function (PNF) defined as a permanent lack of function of the allograft; length of hospital stay and postoperative complications of all kind (28). Estimated glomerular filtration rate (eGFR) at one week and three and twelve months calculated with the CKD-EPI formula; measured GFR employing Iodinethalamate (Groningen), CrEDTA (Aarhus) and Iohexol (Oslo) at twelve months; readmissions at three and twelve months, graft survival and patient survival at twelve months.;
The investigators predefined four substudies being: Cardiac biomarkers in renal transplantation, Volatile vs Intravenous anaesthetic agent; Predictive value of urinary Biomarkers in a deceased donor kidney transplantation cohort to predict PNF, DGF, Acute rejection and long term graft function and outcome; Association between intraoperative haemodynamics and vasopressor use and graft outcome; Postoperative delirium, volatile vs Intravenous anaesthetic agent (Groningen, Aarhus);
Exclusion Criteria:
Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.
Drug: propofol
Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.
Drug: sevoflurane
General anesthesia with sevoflurane
General anesthesia with propofol
Incidence of delayed graft function and/or one year acute rejection
DGF is defined as need of dialysis first 7 days after transplantation Acute rejection up to 1 year after transplantation, defined by the modified BANFF 2013 classification and must be associated with decline in kidney function and treatment.
Time frame: DGF: 7 days after transplantation Acute rejection: up to 1 year after transplantation
Estimated Glomerular Filtration Rate (GFR)
calculated with the CKD-EPI formula
Time frame: 7 days after transplantation, 3 months after transplantation, 1 year after transplantation
incidence of primary non function (PNF)
PNF is defined as permanent lack of function of the transplanted kidney. This kidney will not gain function after transplantation
Time frame: up to 3 months after transplantation
Incidence of funactional Delayed Graft Function
Absence of a daily decrease of at least 10% in serum creatinine for at least three consecutive days
Time frame: 7 days after transplantation
Length of hospital stay
Days
Time frame: From day of transplantation until the day of discharge, assessed up to 60 days
Postoperative complications of all kind
Time frame: from the day of transplantation until the day of discharge, assessed up to 60 days
hospital readmissions after transplantation
Time frame: 3 months after transplantation and between 3 months and 1year after transplantation
Graft survival
Time frame: up to 1 year after transplantation
All-cause mortality
Mortality due to any cause
Time frame: up to 1 year after transplantation
measured GFR employing Iodinethalamate (Groningen), CrEDTA (Aarhus) and Iohexol (Oslo) at twelve months
In a subpopulation of Groningen, Aarhus, Oslo; employing Iodinethalamate (Groningen), CrEDTA (Aarhus) and Iohexol (Oslo)
Time frame: 1 year after transplantation
Cardiac biomarkers in renal transplantation, Volatile vs Intravenous anesthetic agent. A substudy of the VAPOR-2 study; a multicenter randomized controlled study
The aim of our study is to investigate cardiac biomarkers in kidney transplant recipients using two different anesthesia regimen and to investigate whether there is any difference in outcome. In this substudy we will investigate the levels and thresholds of cardiac biomarkers (Troponin-T and pro-BNP) at three time points (day 0, day 1 and day3) with two different anesthetic management (intravenous or inhalational), and the impact of outcome and MACE (major adverse cardiac events). The findings in this study may provide important information for the transplant team about which anesthesia is best suited for kidney transplant recipients with cardiovascular comorbidity.
Time frame: From enrollment to 1 year follow-up
Predictive value of urinary Biomarkers in a deceased donor kidney transplantation cohort to predict PNF, DGF, Acute rejection and long term graft function and outcome
The donation and transplantation procedure is inevitably accompanied by harmful processes that impact the kidney's viability. Ischemia reperfusion injury (IRI) is one of the main harmful processes which frequently results in complications and reduced kidney function after transplantation, such as delayed graft function (DGF) or primary non-function (PNF) . It is therefore important to detect and prevent damage as a result of IRI. An improved and earlier detection of IRI-induced damage might allow therapeutic measures and improve renal function and patient outcome on a longer term. We studied several biomarkers in a living donor kidney transplantation (LDKT) cohort. We will now proceed whit analysis of the release pattern and predictive value of KIM-1, H-FABP, NAG and NGAL and novel biomarkers on short- and long-term graft outcome after deceased donor kidney transplantation
Time frame: from enrollement to follow-up of 1 year
Association between intraoperative haemodynamics and graft outcome
Perioperative hemodynamic and fluid management remains one of the most debated topics in modern anesthesia, particularly in the context of kidney transplantation, where there is currently no consensus on optimal blood pressure targets. This is further complicated by the fact that the transplanted kidney is denervated, resulting in impaired autoregulation and making renal blood flow directly dependent on systemic circulation. Our objective is to identify specific intraoperative hemodynamic parameters that are associated with both short- and long-term graft outcomes. To achieve this, we will analyze continuous intraoperative hemodynamic data and assess their relationship with delayed graft function (DGF), acute rejection (AR), primary non-function (PNF), estimated glomerular filtration rate (eGFR) at 3 and 12 months, and overall graft survival.
Time frame: from enrollement to 1 year follow-up
Incidence of postoperative delirium assessed by RASS in PACU and CAM on postoperative days 1-2 between volatile vs Intravenous anaesthetic agent, A substudy of the VAPOR-2 study
This substudy investigates the incidence of postoperative delirium after renal transplantation in a randomized controlled trial with two groups anesthetized using either Propofol or Sevoflurane. Postoperative delirium will be screened using RASS (Richmond agitation sedation score) in the PACU and CAM (Confusion assessment method) during the first two postoperative days on the ward. The findings from this study will provide information about the incidence of postoperative delirium following renal transplantation. Data may provide information about differences depending on the choice of anesthetic agent - Propofol versus Sevoflurane.
Time frame: From day of transplantation until 2 days postoperative
Plan to share: Yes — Upon completion of the study and primary data analysis, the dataset will be anonymized and made openly accessible through a public data repository
Supporting information: Study protocol, Sap, Icf
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen